NexImmune, Inc. is a clinical‐stage biotechnology company focused on developing novel T‐cell immunotherapies to treat cancer, autoimmune disease and persistent viral infections. The company’s core innovation is its proprietary artificial thymic organoid (ATO) platform, which generates naïve T cells capable of recognizing specific antigens. By guiding T‐cell development in vitro, NexImmune aims to create targeted, high‐potency therapeutic candidates that leverage the body’s natural immune response.
The company’s pipeline includes multiple product candidates at various stages of development. Among these, NexImmune is advancing programs designed to target tumor‐associated antigens in solid tumors and hematologic malignancies. In parallel, the firm is exploring applications in chronic viral infections, including hepatitis B virus, and in certain autoimmune disorders where selective modulation of T‐cell responses may restore immune balance. Preclinical studies have demonstrated the ability of ATO‐derived T cells to expand and persist in vivo, laying the groundwork for early‐stage clinical trials.
Founded in 2015 and headquartered in Gaithersburg, Maryland, NexImmune went public on the NASDAQ under the ticker NEXI in mid‐2020. The company conducts its research and development activities in the United States, with ongoing collaborations and clinical trials spanning North America and select international sites. NexImmune’s management team comprises seasoned biotechnology executives and immunology researchers, many of whom have held leadership positions at leading cell therapy and gene therapy organizations.
As a clinical‐stage enterprise, NexImmune continues to expand its ATO platform capabilities, seeking to address high‐unmet‐need indications where current treatments offer limited benefit. With a strategic focus on partnerships and pipeline diversification, the company aims to translate its platform science into multiple off‐the‐shelf and personalized T‐cell therapies for patients worldwide.
AI Generated. May Contain Errors.
